BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 22752083)

  • 1. Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters.
    Gobbi PG; Bergonzi M; Bassi E; Merli F; Coriani C; Stelitano C; Iannitto E; Federico M
    Oncol Rep; 2012 Sep; 28(3):815-20. PubMed ID: 22752083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.
    Gobbi PG; Bergonzi M; Bassi E; Merli F; Coriani C; Federico M
    Hematol Oncol; 2013 Sep; 31(3):151-5. PubMed ID: 23108910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma.
    Gobbi PG; Broglia C; Di Giulio G; Mantelli M; Anselmo P; Merli F; Zinzani PL; Rossi G; Callea V; Iannitto E; Paulli M; Garioni L; Ascari E
    Cancer; 2004 Oct; 101(8):1824-34. PubMed ID: 15372482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance.
    Gobbi PG; Ghirardelli ML; Solcia M; Di Giulio G; Merli F; Tavecchia L; Bertè R; Davini O; Levis A; Broglia C; Maffè GC; Ilariucci F; Dore R; Ascari E
    J Clin Oncol; 2001 Mar; 19(5):1388-94. PubMed ID: 11230483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.
    Gobbi PG; Bassi E; Bergonzi M; Merli F; Coriani C; Iannitto E; Luminari S; Polimeno G; Federico M
    Hematol Oncol; 2012 Dec; 30(4):194-9. PubMed ID: 22271092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.
    Gobbi PG; Valentino F; Bassi E; Coriani C; Merli F; Bonfante V; Marchianò A; Gallamini A; Bolis S; Stelitano C; Levis A; Federico M; Angrilli F; Di Giulio G; Corazza GR
    Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):396-402. PubMed ID: 21729691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
    Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
    Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin's disease: a quantitative evaluation by computed tomography of tumor burden.
    Torricelli P; Grimaldi PL; Fiocchi F; Federico M; Romagnoli R
    Clin Imaging; 2004; 28(4):239-44. PubMed ID: 15246472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor burden in Hodgkin's lymphoma: much more than the best prognostic factor.
    Gobbi PG
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):17-23. PubMed ID: 24290380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive value of Hodgkin's lymphoma tumor burden in present].
    Kulyova SA; Karitsky AP
    Vestn Ross Akad Med Nauk; 2014; (11-12):67-71. PubMed ID: 25971129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
    Smolewski P; Robak T; Krykowski E; Blasiñska-Morawiec M; Niewiadomska H; Pluzanska A; Chmielowska E; Zambrano O
    Clin Cancer Res; 2000 Mar; 6(3):1150-60. PubMed ID: 10741746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
    Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
    Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy.
    Smith RS; Chen Q; Hudson MM; Link MP; Kun L; Weinstein H; Billett A; Marcus KJ; Tarbell NJ; Donaldson SS
    J Clin Oncol; 2003 May; 21(10):2026-33. PubMed ID: 12743158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
    J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.
    Montalbán C; García JF; Abraira V; González-Camacho L; Morente MM; Bello JL; Conde E; Cruz MA; García-Sanz R; García-Laraña J; Grande C; Llanos M; Martínez R; Flores E; Méndez M; Ponderós C; Rayón C; Sánchez-Godoy P; Zamora J; Piris MA;
    J Clin Oncol; 2004 May; 22(9):1664-73. PubMed ID: 15117989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Computerized tomography in the staging and the follow-up of Hodgkin's lymphoma of the thorax].
    Garribba AP; Ettorre GC; Francioso G; Villani PC; Angone G; Liso V; Specchia G; Pavone V; Capalbo S
    Radiol Med; 1990 Dec; 80(6):859-64. PubMed ID: 2281167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.
    Castellani MR; Cefalo G; Terenziani M; Aliberti G; Maccauro M; Alessi A; Villano C; Bombardieri E
    Q J Nucl Med; 2003 Mar; 47(1):22-30. PubMed ID: 12714951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.